Adjunctive Octreotide for Moderate-to-Severe Acute Pancreatitis: A Prospective Comparative Study in Iraqi Patients

Rawaa Abdulzahra Mohammed  Hussein; Nabeel Jasim Sagban; Sajida Hussein Ismail

doi:10.54133/ajms.v10i1.2786

Authors

Rawaa Abdulzahra Mohammed Hussein Department of Pharmacy, Oncology Teaching Hospital, Medical City, Baghdad, Iraq
Nabeel Jasim Sagban Department of Surgery, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq
Sajida Hussein Ismail Department of Pharmacology and Toxicology, College of Pharmacy, Al Turath University, Baghdad, Iraq

DOI:

https://doi.org/10.54133/ajms.v10i1.2786

Keywords:

Acute pancreatitis, Conservative management, Complications, Iraq, Octreotide, Somatostatin analogue

Abstract

Background: Acute pancreatitis (AP) remains a major cause of gastrointestinal hospitalization and can progress to systemic inflammatory response, organ failure, and death. Management is primarily supportive. Octreotide has been proposed to reduce pancreatic exocrine secretion and inflammatory progression, but clinical effectiveness is still controversial, with some studies suggesting it may help reduce complications and improve outcomes in patients with acute pancreatitis. Objective: To investigate the effect of octreotide in the treatment of moderate-to-severe acute pancreatitis in Iraqi patients. Methods: A prospective, pragmatic comparative study was conducted at Baghdad Teaching Hospital, Medical City, Iraq (November 2021–November 2023). Seventy-eight patients with moderate-to-severe AP were included and allocated into a control group receiving conservative management (n=40) and an octreotide group receiving conservative management plus octreotide (0.1 mg subcutaneously every 6 hours for 7 days) (n=38). Outcomes included in-hospital complications, discharge status, mortality, and length of hospital stay. Results: Baseline characteristics were comparable between groups (p>0.05). Complication rates were numerically lower in the octreotide group, including ARDS (7.89% vs. 17.5%), septicemia (18.42% vs. 32.5%), renal failure (5.26% vs. 10.0%), abscess (2.63% vs. 7.5%), and pseudocyst (7.89% vs. 15.0%), though differences were not statistically significant (p>0.05). Mortality was lower with octreotide (10.5% vs. 17.5%). Cure and discharge occurred in 81.57% of octreotide-treated patients versus 65.0% in controls. The mean hospital stay was 12.95±5.74 vs. 11.05±5.31 days, respectively (p=0.133). Conclusions: Octreotide showed favorable clinical trends in reducing complications and improving discharge outcomes, but larger randomized trials are needed to confirm efficacy.

Downloads

Download data is not yet available.

References

Zerem E, Kurtcehajic A, Kunosić S, Malkočević DZ, Zerem O. Current trends in acute pancreatitis: Diagnostic and therapeutic challenges. World J Gastroenterol. 2023;29(18):2747. doi: 10.3748/wjg.v29.i18.2747. DOI: https://doi.org/10.3748/wjg.v29.i18.2747

Metri A, Bush N, Singh VK. Predicting the severity of acute pancreatitis: Current approaches and future directions. Surg Open Sci. 2024;19:109-117. doi: 10.1016/j.sopen.2024.03.012. DOI: https://doi.org/10.1016/j.sopen.2024.03.012

Colvin SD, Smith EN, Morgan DE, Porter KK. Acute pancreatitis: an update on the revised Atlanta classification. Abdom Radiol (NY). 2020;45(5):1222-1231. doi: 10.1007/s00261-019-02214-w. DOI: https://doi.org/10.1007/s00261-019-02214-w

Mihoc T, Latcu SC, Secasan CC, Dema V, Cumpanas AA, Selaru M, et al. Pancreatic morphology, immunology, and the pathogenesis of acute pancreatitis. Biomedicines. 2024;12(11):2627. doi: 10.3390/biomedicines12112627. DOI: https://doi.org/10.3390/biomedicines12112627

Komara NL, Paragomi P, Greer PJ, Wilson AS, Breze C, Papachristou GI, et al. Severe acute pancreatitis: capillary permeability model linking systemic inflammation to multiorgan failure. Am J Physiol Gastrointest Liver Physiol. 2020;319(5):G573-G583. doi: 10.1152/ajpgi.00285.2020. DOI: https://doi.org/10.1152/ajpgi.00285.2020

Sissingh NJ, de Rijk FEM, Timmerhuis HC, Umans DS, Anten MGF, Bouwense SAW, et al. Gallstones as a cause in presumed acute alcoholic pancreatitis: observational multicentre study. Br J Surg. 2024;111(5):znae107. doi: 10.1093/bjs/znae107. DOI: https://doi.org/10.1093/bjs/znae107

Mittal N, Oza VM, Muniraj T, Kothari TH. Diagnosis and management of acute pancreatitis. Diagnostics. 2025;15(3):258. doi: 10.3390/diagnostics15030258. DOI: https://doi.org/10.3390/diagnostics15030258

Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, et al. Acute pancreatitis: diagnosis and treatment. Drugs. 2022;82(12):1251-1276. doi: 10.1007/s40265-022-01766-4. DOI: https://doi.org/10.1007/s40265-022-01766-4

Song Y, Lee SH. Recent treatment strategies for acute pancreatitis. J Clin Med. 2024;13(4):978. doi: 10.3390/jcm13040978. DOI: https://doi.org/10.3390/jcm13040978

Huang Y, Badurdeen DS. Acute pancreatitis review. Turk J Gastroenterol. 2023;34(8):795-801. doi: 10.5152/tjg.2023.23175. DOI: https://doi.org/10.5152/tjg.2023.23175

Rojas-Victoria EJ, Hernández-Ruiz SI, García-Perdomo HA. Effectiveness of the pharmacological therapy to prevent post ERCP acute pancreatitis: a network meta-analysis. Expert Rev Gastroenterol Hepatol. 2024;18(4-5):203-215. doi: 10.1080/17474124.2024.2345640. DOI: https://doi.org/10.1080/17474124.2024.2345640

Zhang C, Li G, Lu T, Liu L, Sui Y, Bai R, et al. The interaction of microbiome and pancreas in acute pancreatitis. Biomolecules. 2023;14(1):59. doi: 10.3390/biom1401005. DOI: https://doi.org/10.3390/biom14010059

Holst-Hansen T, Nielsen PY, Jensen MH, Mandrup-Poulsen T, Trusina A. Tipping-point transition from transient to persistent inflammation in pancreatic islets. NPJ Syst Biol Appl. 2024;10(1):102. doi: 10.1038/s41540-024-00427-4. DOI: https://doi.org/10.1038/s41540-024-00427-4

Chen F, Xu Y, Wang Z. Ulinastatin combined with somatostatin enhances disease control and modulates serum inflammatory factors in patients with severe pancreatitis. Am J Transl Res. 2023;15(9):5797. PMID: 37854214.

Sun H, Shao J. Effect of Somatostatin Combined with Modified Dachengqi Decoction on Intestinal Function and Inflammatory Factors (TNF-α, IL-6, and IL-8) in Acute Pancreatitis. 2024. Pakistan J Zool. 2024;56:3397-3404. doi: 10.17582/journal.pjz/20230804172924. DOI: https://doi.org/10.17582/journal.pjz/20230804172924

Uhl W, Büchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45(1):97-104. doi: 10.1136/gut.45.1.97. DOI: https://doi.org/10.1136/gut.45.1.97

Hey-Hadavi J, Velisetty P, Mhatre S. Trends and recent developments in pharmacotherapy of acute pancreatitis. Postgrad Med. 2023;135(4):334-344. doi: 10.1080/00325481.2022.2136390. DOI: https://doi.org/10.1080/00325481.2022.2136390

Trikudanathan G, Yazici C, Phillips AE, Forsmark CE. Diagnosis and management of acute pancreatitis. Gastroenterology. 2024;167(4):673-688. doi: 10.1053/j.gastro.2024.02.052. DOI: https://doi.org/10.1053/j.gastro.2024.02.052

Tenner S, Vege SS, Sheth SG, Sauer B, Yang A, Conwell DL, et al. American College of Gastroenterology Guidelines: Management of acute pancreatitis. Am J Gastroenterol. 2024;119(3):419-437. doi: 10.14309/ajg.0000000000002645. DOI: https://doi.org/10.14309/ajg.0000000000002645

Hamesch K, Hollenbach M, Guilabert L, Lahmer T, Koch A. Practical management of severe acute pancreatitis. Eur J Intern Med. 2025;133:1-13. doi: 10.1016/j.ejim.2024.10.030. DOI: https://doi.org/10.1016/j.ejim.2024.10.030

Hu Q, Hu Y, Tan C, Yang Y, Su H, Huang Z, et al. Acute pancreatitis: mechanisms and therapeutic approaches. Signal Transduct Target Ther. 2026;11(1):15. doi: 10.1038/s41392-025-02394-6. DOI: https://doi.org/10.1038/s41392-025-02394-6

Barreto SG, Habtezion A, Gukovskaya A, Lugea A, Jeon C, Yadav D, et al. Critical thresholds: key to unlocking the door to the prevention and specific treatments for acute pancreatitis. Gut. 2021;70(1):194-203. doi: 10.1136/gutjnl-2020-322163. DOI: https://doi.org/10.1136/gutjnl-2020-322163

Coman LI, Balaban DV, Dumbravă BF, Păunescu H, Marin R-C, Costescu M, et al. Targeting oxidative stress in acute pancreatitis: a critical review of antioxidant strategies. Nutrients. 2025;17(15):2390. doi: 10.3390/nu17152390. DOI: https://doi.org/10.3390/nu17152390

Beij A, Verdonk RC, van Santvoort HC, de-Madaria E, Voermans RP. Acute pancreatitis: An update of evidence-based management and recent trends in treatment strategies. United European Gastroenterol J. 2025;13(1):97-106. doi: 10.1002/ueg2.12743. DOI: https://doi.org/10.1002/ueg2.12743

Gardner AJ, Kristensen SR. A multivariable analysis to predict variations in hospital mortality using systems-based factors of healthcare delivery to inform improvements to healthcare design within the English NHS. Plos One. 2024;19(7):e0303932. doi: 10.1371/journal.pone.0303932. DOI: https://doi.org/10.1371/journal.pone.0303932

Caban M, Zatorski H, Małecka-Wojciesko E. Fluid therapy in acute pancreatitis—Current knowledge and future perspectives. Pharmaceuticals. 2025;18(11):1601. doi: 10.3390/ph18111601. DOI: https://doi.org/10.3390/ph18111601

Malbrain MLNG, Wong A, Nasa P, Ghosh S, (Eds.), Rational use of intravenous fluids in critically ill patients, (eBook), Springer Nature; 2024. doi: 10.1007/978-3-031-42205-8. DOI: https://doi.org/10.1007/978-3-031-42205-8

Ziaka M, Exadaktylos A. Fluid management strategies in critically ill patients with ARDS: a narrative review. Eur J Med Res. 2025;30(1):401. doi: 10.1186/s40001-025-02661-w. DOI: https://doi.org/10.1186/s40001-025-02661-w

Zhu LX, Chen Y, Chen XF, Sheng N, Feng PF. Systematic review and meta-analysis of the clinical efficacy of octreotide in combination with ulinastatin in the treatment of acute pancreatitis. Drugs R D. 2025;25(3):195-207. doi: 10.1007/s40268-025-00518-5. DOI: https://doi.org/10.1007/s40268-025-00518-5

Zeng S, Li Y, Wen L, Li Y, Yao Z, Cao Y, et al. Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis. J Pancreatol. 2025;8(2):106-117. doi: 10.1097/JP9.0000000000000181. DOI: https://doi.org/10.1097/JP9.0000000000000181

Bandyopadhyay S, Samajdar SS, Das S. Ulinastatin for the treatment of severe acute pancreatitis: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):629. doi: 10.1186/s12876-025-04239-6. DOI: https://doi.org/10.1186/s12876-025-04239-6